OBIO ORCHESTRA BIOMED HLDGS INC revenue, earnings and financials

For the quarter ended June 30, 2026, ORCHESTRA BIOMED HLDGS INC reported revenue of $88.0K (down 89.5% from a year earlier), net income of −$23.8M and diluted EPS of −$0.38; over the last four quarters revenue was $32.0M and net income −$59.0M; for the fiscal year ended December 2025 revenue was $33.5M, up 1169.2% on the year before.

OBIO annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $33.5M, gross profit n/a, operating income −$51.8M, net income −$52.7M (margin -157.4%), EPS −$1.11
• Fiscal year ended Dec 2024: revenue $2.64M, gross profit n/a, operating income −$64.3M, net income −$61.0M (margin -2313.3%), EPS −$1.66
• Fiscal year ended Dec 2023: revenue $2.76M, gross profit n/a, operating income −$51.5M, net income −$49.1M (margin -1779.7%), EPS −$1.48
• Fiscal year ended Dec 2022: revenue $3.53M, gross profit n/a, operating income −$32.7M, net income −$33.6M (margin -951.3%), EPS −$2.24
• Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$395K, net income −$379K (margin n/a), EPS −$0.02

OBIO quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $88.0K (down 89.5% year over year), net income −$23.8M, EPS −$0.38
• Quarter ended Mar 31, 2026: revenue $110K (down 87.3% year over year), net income −$20.7M, EPS −$0.33
• Quarter ended Dec 31, 2025 (from the annual report): revenue $30.9M (up 12120.2% year over year), net income $6.25M, EPS $0.28
• Quarter ended Sep 30, 2025: revenue $861K (down 12.8% year over year), net income −$20.8M, EPS −$0.40
• Quarter ended Jun 30, 2025: revenue $836K (up 7.5% year over year), net income −$19.4M, EPS −$0.50
• Quarter ended Mar 31, 2025: revenue $868K (up 40.0% year over year), net income −$18.8M, EPS −$0.49
• Quarter ended Dec 31, 2024 (from the annual report): revenue $253K (down 3.4% year over year), net income −$16.2M, EPS −$0.42
• Quarter ended Sep 30, 2024: revenue $987K (up 135.6% year over year), net income −$15.4M, EPS −$0.41
• Quarter ended Jun 30, 2024: revenue $778K (down 15.0% year over year), net income −$16.0M, EPS −$0.45
• Quarter ended Mar 31, 2024: revenue $620K (down 46.7% year over year), net income −$13.5M, EPS −$0.38
• Quarter ended Dec 31, 2023 (from the annual report): revenue $262K (down 76.2% year over year), net income −$12.8M, EPS −$0.35
• Quarter ended Sep 30, 2023: revenue $419K (down 64.0% year over year), net income −$13.3M, EPS −$0.38
• Quarter ended Jun 30, 2023: revenue $915K (up 128.2% year over year), net income −$12.0M, EPS −$0.35
• Quarter ended Mar 31, 2023: revenue $1.16M (up 34.4% year over year), net income −$10.9M, EPS −$0.40
• Quarter ended Dec 31, 2022 (from the annual report): revenue $1.10M, net income −$9.75M, EPS −$0.34
• Quarter ended Sep 30, 2022: revenue $1.16M, net income −$10.3M, EPS −$0.51
• Quarter ended Jun 30, 2022: revenue $401K, net income −$7.85M, EPS −$0.77
• Quarter ended Mar 31, 2022: revenue $866K, net income −$5.73M, EPS −$0.62
• Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$88.0K, EPS −$0.02
• Quarter ended Sep 30, 2021: revenue n/a, net income −$90.4K, EPS $0.00

OBIO cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$49.0M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$50.6M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$46.1M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$29.3M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$272K, share buybacks n/a

OBIO balance sheet

• Jun 30, 2026: cash $20.5M, total assets $116M, total liabilities $86.3M, shareholders' equity n/a
• Mar 31, 2026: cash $28.4M, total assets $101M, total liabilities $49.7M, shareholders' equity n/a
• Dec 31, 2025: cash $34.7M, total assets $115M, total liabilities $51.5M, shareholders' equity n/a
• Sep 30, 2025: cash $42.0M, total assets $105M, total liabilities $61.1M, shareholders' equity n/a
• Jun 30, 2025: cash $18.7M, total assets $42.8M, total liabilities $42.5M, shareholders' equity n/a
• Mar 31, 2025: cash $18.3M, total assets $59.1M, total liabilities $42.2M, shareholders' equity n/a
• Dec 31, 2024: cash $22.3M, total assets $76.2M, total liabilities $43.2M, shareholders' equity n/a
• Sep 30, 2024: cash $25.6M, total assets $75.3M, total liabilities $29.1M, shareholders' equity n/a

What is OBIO's revenue?

ORCHESTRA BIOMED HLDGS INC reported $32.0M of revenue over its last four quarters, through June 30, 2026.

Is OBIO profitable?

No. ORCHESTRA BIOMED HLDGS INC lost $59.0M over the last four quarters.

What is OBIO's EPS?

Diluted earnings per share over the last four quarters were −$0.83; −$0.38 in the latest quarter.

OBIO ownership and insider trades · All stocks